"10.1371_journal.pone.0086106","plos one","2014-01-20T00:00:00Z","Reiji Kojima; Tatsukuni Ohno; Motoyasu Iikura; Toshiro Niki; Mitsuomi Hirashima; Keichi Iwaya; Hitoshi Tsuda; Shigeaki Nonoyama; Akio Matsuda; Hirohisa Saito; Kenji Matsumoto; Susumu Nakae","Department of Basic Pathology, National Defense Medical College, Saitama, Japan; Department of Pediatrics, National Defense Medical College, Saitama, Japan; Department of Allergy and Immunology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan; Departments of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Takamatsu, Japan; Research Center, GalPharma Company, Takamatsu, Japan; Laboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency, Saitama, Japan","Conceived and designed the experiments: TO MI S. Nakae. Performed the experiments: RK TO. Analyzed the data: RK TO S. Nakae. Contributed reagents/materials/analysis tools: MI TN MH KI HT S. Nonoyama AM HS KM. Wrote the paper: RK TO S. Nakae.","Toshiro Niki and Mitsuomi Hirashima are board members of GalPharma Co., Ltd. The authors have the following patents related to material pertinent to this article: Novel modified galectin 9 proteins and use thereof which is applied by GalPharma and issued in Japan (4792390), the USA (8,268,324), EPC (1736541), Canada (2,561,696), India (239130), and Korea ((10-1222281) as of 2013.12.2). The authors have the following products related to material pertinent to this article: stable-form Gal-9. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Reiji Kojima","RK",12,TRUE,3,2,3,3,TRUE,TRUE,TRUE,2,"9;11",TRUE
